PSMA-based therapies have offer a new ray of hope

1
PSMA-based therapies have been proven effective
for patients with advanced prostate cancer for
whom surgical and other medical options have
already exhausted themselves. They offer a new
ray of hope. The Department of Nuclear Medicine
at Fortis Memorial Research Institute (FMRI),
Gurugram, India, has treated more than 30 new
patients of Castration Resistance Prostate Cancer
(CRPC) with Ac225 PSMA Therapy. The results are
extremely promising with 75-80 of patients
showing evidences of significant radiological and
biochemical response with prolonged duration of
response.
2
Cecific membrane antigen-positive melinical
trials have shown that targeted radiation therapy
225Ac-PSMA-617 has produced high response rate
among men with with prostate-sptastatic,
castration-resistant prostate cancer.
3
PSMA-based therapy is an effective treatment
option that is offered to patients with
metastasised prostate cancer with disease
progression despite hormone therapy or
chemotherapy.
4
At the 2018 Annual Meeting of the Society of
Nuclear Medicine Molecular Imaging (SNMMI), a
research was presented that demonstrated the
benefit of providing earlier Lu-177 PSMA
Radioligand Therapy to patients with metastatic
prostate cancer, which until now was only used on
patients with advanced stage of the disease. The
research demonstrated a potential survival
benefit and a superior response after early
initiation of the therapy - patients who
demonstrated a PSA decline of more than 50 after
at least two PRLT cycles lived significantly
longer.
5

• For more information do call Dr. Ishita Sen on
  91 98111 27080, or write
• to us at info_at_nuclearmedicinetherapy.in. You can
  also visit
• our website to request for an opinion
• www.nuclearmedicinetherapy.in